ABSTRACT
Background The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated TMAs from prostate cancer samples obtained from multiple institutions across several global locations.
Methods Three separate TMA sets were built that differ by purpose and disease state.
Results The intended use of TMA1 is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration resistant metastatic disease, and to compare molecular properties of high risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 was designed to address questions regarding risk of castration resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3’s intended use is to assess and better understand the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases.
Conclusion The GAP1-UTMA project has succeeded in combining a large set of rare tissue specimens from 501 prostate cancer patients with rich clinical annotation.
Impact This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We have developed a set of TMAs from a multi-institutional initiative supported by the Movember Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All centers received ethical review board permission to use patient material and conduct this study Comite d ethique de la recherche du CHUM (CE.14.128) the Institutional Review Board of the : JHU School of Medicine s the UMBMC the VA Greater Los Angeles (Department of Veterans Affairs PCC#2015-040408) the Ethics Committee of Hospital District of Helsinki and Uusimaa (84/13/03/00/2014; 3 30.01.2015) the Hospital District of Southwest Finland (number T206/2014) National Supervisory Authority for Welfare and Health for HUS and TYKS (VALVIRA 8008/06.01.03/2014) the Regional Committees for Medical and Health Research Ethics for OUH (REC 2013/1713) and Center for Healthcare Ethics for Cedar Sinai (Pro00033387 and Pro00020577). Patient informed consents were obtained as required by individual institutional ethical review boards (CHUM CE12.216 HUS TYKS and University of Washington Cedar Sinai) or waivers were granted (JHU OUH both VA Health Care System and UMBMC).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: The creation of this resource was funded by Movember. JHU is supported by U.S. NIH/NCI SPORE in Prostate Cancer: P50CA58236, the U.S. Department of Defense Prostate Cancer Research Program (PCRP): W81XWH-18-2-0015 to A.M.D. The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Oncology Tissue Services Laboratory supported by U.S. NIH/NCI P30 CA006973. CRCHUM is supported by the FRQS. Biobanking at the CRCHUM was done in collaboration with the Réseau de recherche sur le cancer of the Fonds de Recherche Québec - Santé (FRQ-S) affiliated to the Canadian Tissue Repository Network (CTRNet). F.S. the Raymond Garneau Chair in Prostate Cancer. D.T. is supported by the Chercheure boursière clinicienne niveau junior 2 of the FRQ-S awards. UW tissue acquisition was supported by U.S. NIH/NCI SPORE in Prostate Cancer: P50CA97186 and the UW Institute for Prostate Cancer Research.
Conflict of interest disclosure: The authors declare no potential conflicts of interest
Data Availability
The process to access the UTMA resource is outlined in Supplemental Figure 1. As part of a collaboration, the biomarker proposal form will be located on the Prostate Cancer Biorepository Network (PCBN) (25) website (www.prostatebiorepository.org).
